Series B

A South Korean AI firm is transforming Wall Street and the insurance industry with strategic funding from AWS and a unique human-centric technology.

New data reveals a stark split in private markets. Capital floods into infrastructure and AI, while concerns over PE exits and real estate persist.

SCALE AI's record funding fuels 44 new projects, aiming to accelerate homegrown AI and secure Canada's digital future amid fierce global competition.

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

A new $50M fund says the old VC playbook is broken. We analyze if its AI-first model offers superior returns or is just a high-stakes bet on the future.

Nasdaq-listed Society Pass is ditching its e-commerce roots for the AI gold rush. Is this a savvy M&A masterstroke or a risky gamble in a capital-heavy arena?

RecycLiCo's new R&D hub is more than just a building; it's a strategic play in the high-stakes game of critical mineral independence.

Professor Youmin Xi's recent honor signals more than academic success. It marks a strategic blueprint for cultivating the next generation of life science leaders.

New data reveals a massive, quiet market for spiritual wellness among younger generations. Investors are taking note of platforms monetizing this trend.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

With a fresh $62M in funding, WELLSTAR is accelerating its AI and acquisition strategy ahead of a planned 2026 spinout, aiming to rewire Canadian healthcare.

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

A key accelerator selection puts South Korean startup ALL CONEC and its AI-driven dental platform in the spotlight, backed by Oracle's cloud power.

Virax secured a $5M runway for its Long COVID diagnostics, but the deal's terms reveal a high-stakes gamble involving significant shareholder dilution.